We are live on ! Find out more
DSGN icon

Design Therapeutics
DSGN

60 hedge funds and large institutions have $773M invested in Design Therapeutics in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

480% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 5

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

86% more capital invested

Capital invested by funds: $415M → $773M (+$358M)

15% more funds holding

Funds holding: 52 → 60 (+8)

14.14% more ownership

Funds ownership: 50.85% → 64.98% (+14%)

Holders
60
Holders Change
+8
Holders Change %
+15.38%
% of All Funds
0.92%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
13
Increased
29
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$15.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$13.4M
3
Principal Financial Group
Principal Financial Group
Iowa
+$5.18M
4
EC
EcoR1 Capital
California
+$4.98M
5
ACA
Avoro Capital Advisors
New York
+$2.88M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$11.4M
2
CS
Credit Suisse
Switzerland
-$3.47M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.72M
4
Citadel Advisors
Citadel Advisors
Florida
-$650K
5
OCA
Octagon Capital Advisors
New York
-$219K
Name Holding Trade Value Shares
Change 		Change in
Stake
SOCM
1
SR One Capital Management
Pennsylvania
$120M +$96.6M +5,626,476 New
CAM
2
Cormorant Asset Management
Massachusetts
$116M +$1.3M +75,603 +1%
LGM
3
Logos Global Management
California
$59.4M – – –
Citadel Advisors
4
Citadel Advisors
Florida
$54.3M -$650K -37,828 -1%
BlackRock
5
BlackRock
New York
$47.4M +$15.5M +902,960 +69%
RCM
6
RA Capital Management
Massachusetts
$46.8M – – –
EC
7
EcoR1 Capital
California
$46.1M +$4.98M +289,899 +16%
Vanguard Group
8
Vanguard Group
Pennsylvania
$40M +$13.4M +782,301 +72%
ACA
9
Avoro Capital Advisors
New York
$35M +$2.88M +167,782 +11%
BBA
10
Baker Bros. Advisors
New York
$30.8M – – –
Fidelity Investments
11
Fidelity Investments
Massachusetts
$21.4M – – –
Janus Henderson Group
12
Janus Henderson Group
United Kingdom
$19.1M +$1.85K +108 +0%
Wellington Management Group
13
Wellington Management Group
Massachusetts
$18.3M -$1.72M -100,050 -10%
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$16.9M -$11.4M -661,303 -46%
VC
15
Vivo Capital
California
$11.4M – – –
Principal Financial Group
16
Principal Financial Group
Iowa
$11.2M +$5.18M +301,944 +137%
AG
17
Artal Group
Luxembourg
$8.56M – – –
EAM
18
Eventide Asset Management
Massachusetts
$8.56M – – –
Geode Capital Management
19
Geode Capital Management
Massachusetts
$7.52M +$1.6M +93,409 +36%
State Street
20
State Street
Massachusetts
$7.33M +$2.24M +130,653 +62%
RSCM
21
Rock Springs Capital Management
Maryland
$7.18M +$20.6K +1,197 +0.4%
HA
22
HHLR Advisors
Cayman Islands
$6.02M – – –
Northern Trust
23
Northern Trust
Illinois
$4.54M +$1.53M +89,183 +73%
Norges Bank
24
Norges Bank
Norway
$4.28M – – –
Adage Capital Partners
25
Adage Capital Partners
Massachusetts
$3.53M – – –
1
2 3

DSGN Hedge Fund Activity: Q4 2021 in Review

60 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q4 2021, worth a combined $773M — up 86% from $415M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new DSGN positions and 5 closed out — a net gain of 8 holders — while 29 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $15.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $11.4M.

  • 60 institutional investors held Design Therapeutics (DSGN) as of Q4 2021, up from 52 in Q3 2021.
  • Funds reported $773M of Design Therapeutics stock for Q4 2021, up 86% quarter-over-quarter.
  • 13 funds opened new Design Therapeutics positions in Q4 2021 and 5 closed out, a net change of +8 holders.
  • The largest Design Therapeutics buyer in Q4 2021 was BlackRock, an estimated $15.5M added.
  • The largest Design Therapeutics seller in Q4 2021 was T. Rowe Price Associates, an estimated $11.4M sold.

Based on aggregated 13F filings for Q4 2021.